GSK wants to double Shingrix sales, and a new FDA okay could helpThe FDA has approved GlaxoSmithKline’s shingles vaccine Shingrix for use in people aged under 50 who are immunocompromised Share XGSK wants to double Shingrix sales, and a new FDA okay could helphttps://pharmaphorum.com/news/gsk-wants-to-double-shingrix-sales-and-a-new-fda-okay-could-help/
Boost for AZ as Ultomiris gets CHMP nod for expanded labelFresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion Share XBoost for AZ as Ultomiris gets CHMP nod for expanded labelhttps://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/
NHS sets aside £340m for new Innovative Medicines FundNHS England has matched its financial backing of the Cancer Drugs Fund (CDF) with an equivalent pot of Share XNHS sets aside £340m for new Innovative Medicines Fundhttps://pharmaphorum.com/news/nhs-sets-aside-340m-for-new-innovative-medicines-fund/
Roche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readoutPhase 3 results with Roche’s amyloid-targeting Alzheimer’s drug gantenerumab may not be due until the second half of Share XRoche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readouthttps://pharmaphorum.com/news/roche-talking-to-fda-as-alzheimers-drug-moves-towards-2022-readout/
NICE changes its mind on rare bile duct cancer drug from IncyteIncyte’s Pemazyre has become the first targeted therapy available for NHS patients with cholangiocarcinoma or bile duct cancer, Share XNICE changes its mind on rare bile duct cancer drug from Incytehttps://pharmaphorum.com/news/nice-changes-its-mind-on-rare-bile-duct-cancer-drug-from-incyte/
Bluebird claims EU nod for rare disease therapy SkysonaBluebird bio has its first approval for Skysona (formerly Lenti-D), its gene therapy for children with the rare Share XBluebird claims EU nod for rare disease therapy Skysonahttps://pharmaphorum.com/news/bluebird-claims-eu-nod-for-rare-disease-therapy-skysona/
Novartis eyes New Year verdict from FDA on delayed LeqvioNovartis has revealed that the FDA has accepted its resubmission for cholesterol-lowering drug Leqvio – rejected unexpectedly by Share XNovartis eyes New Year verdict from FDA on delayed Leqviohttps://pharmaphorum.com/news/novartis-eyes-new-year-verdict-from-fda-on-delayed-leqvio/
EMA starts review of latecomer GSK/Sanofi COVID-19 vaccineThe EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started Share XEMA starts review of latecomer GSK/Sanofi COVID-19 vaccinehttps://pharmaphorum.com/news/ema-starts-review-of-latecomer-gsk-sanofi-covid-19-vaccine/
Hard times at Ardelyx as FDA rejects kidney disease drug tenapanorThe FDA has taken a longer than usual look at Ardelyx’s regulatory submission for tenapanor, a drug for Share XHard times at Ardelyx as FDA rejects kidney disease drug tenapanorhttps://pharmaphorum.com/news/hard-times-at-ardelyx-as-fda-rejects-kidney-disease-drug-tenapanor/
